Jean Katow, M.D. is a board-certified ophthalmologist who specializes in general ophthalmology, ophthalmic plastics, and reconstructive surgery. She obtained her Bachelors degree at the University of California, Los Angeles and subsequently attended the University of California, Davis for her Medical Degree. She completed her residency in ophthalmology at the University of Louisville and her fellowship in ophthalmic plastics at the University of Cincinnati. Dr. Katow has been practicing for nearly 20 years and is involved in humanitarian missions to foreign countries in need of medical care. She is a member of the American Academy of Ophthalmology, the California Association of Ophthalmology, and the Los Angeles Ophthalmological Society.
University of California, Davis Medical School Davis, California 95616
University of Southern California, 3551 University Avenue, Los Angeles, California 90089
Graduate Courses, Biological Sciences
University of California, 405 Hilgard Avenue, Westwood, California 90024 B.A., Zoology
Ophthalmic Plastics and Reconstructive Surgery Fellowship University of Cincinnati, Dept. of Ophthalmology, Cincinnati, Ohio. Dwight Kulwin, M.D., University of Cincinnati, The Barrett Center, 234 Goodman, ML 670, Cincinnati, Ohio 45267
Ophthalmology Residency, University of Louisville School of Medicine, Department of Ophthalmology, 301 East Muhammed Ali Boulevard, Louisville, KY 40202
Flexible Residency, White Memorial Medical Center, 1720 Brooklyn Avenue, Los Angeles, CA 90033
Board Certified in Ophthalmology – May 1988
California, Ohio, Hawaii
October 2001 to December 2001
Evaluation of the efficacy and safety of Ketotifen Fumarate 0.025% Ophthalmic Solution Compared to Vehicle Placebo in a Pediatric Population in the Allergen Challenge Model of Allergic Conjunctivitis, Following a Single Dose and Four Week Treatment. Norvartis Ophthalmics.
May 2001 to August 2001
Lumigan Early Experience Data Study 2001. Allergan Inc.
April 2001 to June 2001
A Multi-Center, Randomized, Double Masked, Parallel Group Study Evaluating the Efficacy and Safety of Epinastine Hydrochloride 0.05% Ophthalmic Solution Compared to Vehicle of Epinastine or to Levocabastine 0.05% Ophthalmic Suspension used Twice Daily for Eight Weeks in an Environmental Study in Adult and Pediatric Patients with Seasonal Allergic Conjunctivitis. Allergan Inc.
November 2000 to December 2000
A Dose-Response, Placebo-Controlled Study of Olopatadine Ophthalmic Solutions Using the Conjunctival Antigen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects. Alcon.
St. Vincent Medical Center – Courtesy
2131 West Third Street, Los Angeles, California 90057
Third Street Surgery Center – Active
420 East Third Street, Suite 110, Los Angeles, California 90013
St. Vincent Eye Surgery Institute – Active
201 South Alvarado Street, Suite 718 Los Angeles, California 90057
Good Samaritan Hospital – Courtesy
1225 Wilshire Boulevard., Los Angeles, California 90017
Surgery Center of South Bay – Temporary
23599 Madison Street, Torrance, California 90505
American Academy of Ophthalmology
California Association of Ophthalmology
Los Angeles Ophthalmology Society 1974